House Committee Will Cause Controversy by Bundling Oral Kidney Meds in Medicare Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and Genzyme are expected to fight language in the House draft bill for health care reform that would bundle oral kidney meds into payments for dialysis treatments, Bernstein analyst predicts.
You may also be interested in...
CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
2009 Medicare Budget Plan Pushes For ESA Bundling With Dialysis Rates
Single-payment proposal comes with no details on how the system would function.